One-year treatment with benralizumab in patients with eosinophilic granulomatosis with polyangiitis

P. Scarano (Rome, Italy), C. Cisternino (Rome, Italy), G. Lo Muzio (Rome, Italy), O. Calò (Rome, Italy), A. Sanna (Rome, Italy), A. Steffanina (Rome, Italy), F. De Filippis (Rome, Italy), M. Leporini (Rome, Italy), P. Palange (Rome, Italy), E. Graziani (Rome, Italy)

Source: International Congress 2022 – Update on clinical trials in allergy, asthma and COPD

Session: Update on clinical trials in allergy, asthma and COPD
Session type: Thematic Poster
Number: 3215

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
P. Scarano (Rome, Italy), C. Cisternino (Rome, Italy), G. Lo Muzio (Rome, Italy), O. Calò (Rome, Italy), A. Sanna (Rome, Italy), A. Steffanina (Rome, Italy), F. De Filippis (Rome, Italy), M. Leporini (Rome, Italy), P. Palange (Rome, Italy), E. Graziani (Rome, Italy). One-year treatment with benralizumab in patients with eosinophilic granulomatosis with polyangiitis. 3215

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.